Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Gallus BioPharmaceuticals, LLC (Gallus), a premier
pure-play biologics contract manufacturing organization (CMO) has signed a manufacturing
agreement with Symphogen, A/S (Symphogen), a private biopharmaceutical company developing
recombinant ...
read more
Wednesday, September 16, 2020
Gannex and Galmed have entered into a research agreement aiming at combination therapy of ASC41 and Aramchol for NASH.
read more
Wednesday, November 11, 2020
Galmed Pharmaceuticals and MyBiotics Pharma have entered into a research and development collaboration agreement to identify and optimize the selected microbiome repertoire associated with the response to Aramchol.
read more
Gamida Cell and Lonza announced that the companies have entered into a strategic manufacturing agreement.
read more
Gamma Biosciences announces that it has agreed to make a controlling investment in Mirus Bio.
read more
Gamma Biosciences has announced two additions to the senior management team of Astrea Bioseparations.
read more
Gamma Biosciences, a global life sciences company serving the advanced therapy market, announced the appointment of Terry Pizzie as Chief Executive Officer (CEO) of operating company Astrea Bioseparations. Pizzie succeeds Dr. Steve Burton, who will ...
read more
Wednesday, October 06, 2021
The Gates Biomanufacturing Facility (GBF) announced a continued strategic agreement with Nkarta, Inc. to manufacture clinical supply of therapeutic Natural Killer (NK) cells. As part of this collaboration, GBF will continue to manufacture NKX101, ...
read more
Tuesday, September 30, 2025
Gattefossé has opened a new manufacturing facility in Lufkin, Texas dedicated to pharmaceutical excipient production. The site marks the company’s first excipient manufacturing footprint in the United States, reflecting growing demand for domestic ...
read more
Monday, December 28, 2020
Gattefossé is investing 30 million euros in its industrial operations and announces the construction of a new manufacturing plant in Lufkin, Texas.
read more
Wednesday, March 26, 2025
Gattefossé announced the successful certification of its new manufacturing plant in Lufkin, Texas.
The facility, operational since July 2024, has now achieved three certifications: ISO9001, EFfCI GMP, and EXCiPACT. This marks a significant step ...
read more
Tuesday, October 08, 2024
GBI Biomanufacturing, a Contract Development and Manufacturing Organization (CDMO), and Allterum Therapeutics announced a manufacturing partnership to advance Allterum's lead candidate 4A10 into clinic.
read more
Thursday, November 21, 2024
GBI Biomanufacturing (GBI) announced the expansion of its Drug Product (DP) services, to include automated sterile fill and finish capabilities. GBI has the ability to support clients from clinical trials to commercial launch, for both Drug Substance...
read more
Wednesday, September 10, 2025
GBI Biomanufacturing (GBI) announced a partnership with NanoRetinal, Inc. to develop and manufacture NAR-001, NanoRetinal's proprietary nanoparticle technology designed to restore and/or preserve vision in patients with Inherited Retinal Diseases (...
read more
Wednesday, January 10, 2024
Formerly known as Goodwin Biotechnology, GBI BioManufacturing has proudly announced the execution of its second Master Supply Agreement (MSA) to bring a radioimmunoconjugate product to the commercial market.
read more